Xeris Pharmaceuticals Inc (XERS) saw its stock soar 5.02% in intraday trading on Thursday, following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported record-breaking product revenue and provided an optimistic full-year outlook, sparking investor enthusiasm.
Xeris Biopharma announced Q1 product revenue of $57.802 million, slightly surpassing the IBES estimate of $57.6 million. This performance demonstrates the company's ability to meet and exceed market expectations. Despite reporting a net loss of $9.22 million, or $0.06 per basic share, the focus remained on the top-line growth and future prospects.
Adding to the positive sentiment, Xeris Biopharma provided a robust full-year revenue outlook of $260 million to $275 million. This forward-looking guidance suggests continued growth and potential profitability improvements, which likely contributed to the stock's significant uptick. Investors appear to be betting on Xeris' long-term potential, overlooking the current operating loss of $3.09 million as the company continues to invest in its product pipeline and market expansion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.